AIM:To observe the safety and efficacy of topically administered bevacizumab by ways of subconjunctival injection and eye drops in the treatment of stable corneal neovascularization.

METHODS: With the way of comparison before and after treatment, 32 eyes(25 patients)diagnosed corneal neovascularization(CNV)were administrated bevacizumab by means of subconjunctival injection(2.5mg)and eye drops(4 times/d)15d, which included Alkali burn 6 inpatients 8 eyes, Chronic keratitis 14 inpatients 19 eyes and Simple corneal penetrating injury 5 inpatients 5 eyes. After one month, the patients were treated in the same way again. The treatments were total 3 times. Visual acuity, intraocular pressure(IOP), flare of the anterior chamber, area and length of CNV, corneal pannus, blood pressure and heart rate were observed before and after treatment. The efficacies, safety and frequency of Bevacizumab were discussed before treatments and after the three times treatments ending at 1, 2 and 6mo.

RESULTS: In 32 eyes, IOP, flare of the anterior chamber, blood pressure and heart rate were not changed and corneal pannus were alleviated in varying degrees after the treatments. Compared with the eyes before treatment, the efficacies after the three times treatments in 1, 2 and 3mo were statically significant differences(F=5.574, 6.221, 6.221; P<0.05). After the treatments of one month, visual acuity of 18 eyes were improved above two row(56%); area of CNV of 20 eyes were reduced(63%)and the efficacy was 56%. After the treatments of three months, visual acuity of 23 eyes were improved above two row(72%); area of CNV of 25 eyes were reduced(78%)and the efficacy was 72%. Changes after six months were the same as those after three months. As the different cases of CNV, the therapy of Bevacizumab was efficient. In 32 eyes, the improvements of Bevacizumab treatment in eyesight and CNV were 44% in one time, 56% in two times, and 63% in three times, the times of Bevacizumab treatment were statically significant differences compared one time with two or three times(χ²=46.274, 48.532; P<0.05).

CONCLUSION: The mean of topically administered Bevacizumab by ways of subconjunctival injection and eye drops in the treatment of stable corneal neovascularization is simple, efficient and safe without local or systemic adverse effects in a short phase.